Menu
Menu

References

  1. Criner, GJ, Sue, R, Wright, S, Dransfield, M, Rivas-Perez, H, Wiese, T & Morrissey, B. A multicenter randomized controlled trial of Zephyr® endobronchial valve treatment in heterogeneous emphysema (LIBERATE). Am J Respir Crit Care Med, 2018; 198(9), 1151-1164.
  2. Emphysema. MedlinePlus. https://medlineplus.gov/emphysema.html. Published May 17, 2018. Accessed June 25, 2018.
  3. Gore et al., How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax, 2000; 55(12), 1000-1006.
  4. Gardiner C, et al., Exploring the care needs of patients with advanced COPD: an overview of the literature. Respiratory Medicine, 2010; 104(2), 159-165.
  5. Vermeire, P, The burden of chronic obstructive pulmonary disease. Respiratory Medicine, 2002; 96, S3-S10.
  6. COPD: Challenging Symptoms, Stigma and Stereotypes Patient Survey Fact Sheet. https://www.emphysema.net/Survey_Fact_Sheet.htm. Accessed Oct. 4 2017.
  7. Kemp, SV, Slebos, DJ, Kirk, A, Kornaszewska, M, Carron, K, Ek, L & Briault, A. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med, 2017;196(12), 1535-1543.
  8. Valipour, A, Slebos, DJ, Herth, F, Darwiche, K, Wagner, M, Ficker, JH, & Eberhardt, R. Endobronchial valve therapy in patients with homogeneous emphysema. Results from the IMPACT study. Am J Respir Crit Care Med, 2016;194(9), 1073-1082, and data on file at Pulmonx.
  9. Klooster, K, Hartman, JE, ten Hacken, NH, Slebos, DJ. One-year follow-up after endobronchial valve treatment in patients with emphysema without collateral ventilation treated in the STELVIO trial. Respir 2017; 93(2), 112-121.

Brief Statement: The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. Complications of treatment can include but are not limited to pneumothorax (tear in the lung), worsening of COPD symptoms, hemoptysis, pneumonia, and, in rare cases, death. The Zephyr Valve is contraindicated in patients who have not quit smoking or are allergic to Nitinol (nickel-titanium). Please talk with your physician about other contraindications, warnings, precautions, and adverse events. Only a trained physician can decide whether a particular patient is an appropriate candidate for treatment with the Zephyr Valve.

© 2021-Present Pulmonx Corporation or its affiliates.  All rights reserved. All trademarks are property of their respective owners.

Site Designed by The Deciding Factor, Inc.

References

Follow Us

Follow Us

Brief Statement: The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. Complications of treatment can include but are not limited to pneumothorax (tear in the lung), worsening of COPD symptoms, hemoptysis, pneumonia, and, in rare cases, death. The Zephyr Valve is contraindicated in patients who have not quit smoking or are allergic to Nitinol (nickel-titanium). Please talk with your physician about other contraindications, warnings, precautions, and adverse events. Only a trained physician can decide whether a particular patient is an appropriate candidate for treatment with the Zephyr Valve.

© 2021-Present Pulmonx Corporation or its affiliates.  All rights reserved. All trademarks are property of their respective owners.

Site Designed by The Deciding Factor, Inc.

References